ESMO 2025: A New Era in the Treatment of Muscle Invasive Bladder Cancer. Discussant of LBA2 – Perioperative (Periop) Enfortumab Vedotin plus Pembrolizumab in Participants with Muscle-Invasive Bladder Cancer Who Are Cisplatin-Ineligible: KEYNOTE-9 – U…

Written by

admin

in

  1. ESMO 2025: A New Era in the Treatment of Muscle Invasive Bladder Cancer. Discussant of LBA2 – Perioperative (Periop) Enfortumab Vedotin plus Pembrolizumab in Participants with Muscle-Invasive Bladder Cancer Who Are Cisplatin-Ineligible: KEYNOTE-9  UroToday
  2. Pfizer and Astellas announce positive results from phase 3ev-303 clinical trial for Padcev in combination with Keytruda  TradingView
  3. Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal  The American Journal of Managed Care® (AJMC®)
  4. ESMO25: Padcev, Keytruda regimen given before, after surgery shines in bladder cancer  FirstWord Pharma
  5. KEYNOTE-905: EV/pembrolizumab emerges as new option for cisplatin-ineligible MIBC  Urology Times

Continue Reading

More posts